Symphogen secures additional EUR 41 million

Antibody company Symphogen A/S (Copenhagen, Denmark) secured EUR 41 million ($53.4 million) in an extension of a tranched EUR 100 million ($132.9 million) series E round, bringing the total secured under the round to EUR 141 million ($183.7 million). Existing investors Novo A/S and Danish pension fund PKA led the extension, with participation from Danica Pension, also a Danish pension fund. Symphogen has drawn down EUR 77 million ($89.3 million) of the E round, which it secured in January 2011, and has the balance remaining. ...